Autophagy inhibition in breast cancer cells induces ROS-mediated MIF expression and M1 macrophage polarization

Israel Cotzomi-Ortega1, Oscar Nieto-Yañez2, Imelda Juárez-Avelar2

  • 1Centro de Investigación Biomédica de Oriente (CIBIOR), Instituto Mexicano del Seguro Social (IMSS), Km 4.5 Carretera Atlixco-Metepec HGZ5, Puebla 74360, Mexico; Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla (BUAP), Ciudad Universitaria, Puebla 72570, Mexico.

Cellular Signalling
|July 6, 2021
PubMed

Insights

Inhibiting autophagy in triple-negative breast cancer (TNBC) increases reactive oxygen species (ROS), promoting macrophage migration inhibitory factor (MIF) secretion. This impacts cancer cell signaling and promotes M1 macrophage polarization, offering therapeutic insights.

Area of Science:

  • Oncology
  • Cell Biology
  • Immunology

Background:

  • Autophagy inhibition is a potential cancer therapy, particularly for triple-negative breast cancer (TNBC).
  • Autophagy inhibition can increase macrophage migration inhibitory factor (MIF), a pro-tumorigenic cytokine.
  • The precise role of MIF and the mechanisms of autophagy inhibition in breast cancer require further elucidation.

Purpose of the Study:

  • To investigate the role of MIF in breast cancer subtypes.
  • To elucidate the mechanism by which autophagy inhibition promotes MIF secretion.
  • To assess the effects of secreted MIF on cancer cell signaling and macrophage polarization.

Main Methods:

  • Analysis of MIF mRNA expression in patient tumor samples across breast cancer subtypes.
  • In vitro studies using 66cl4 TNBC cells to assess the impact of autophagy inhibition on ROS levels, MIF expression, and secretion.
  • Investigating the effects of secreted MIF on Akt and ERK phosphorylation in syngeneic cell lines.
  • Quantifying chemokine receptor expression (CD74, CXCR2, CXCR7) in TNBC cells.
  • Assessing macrophage polarization induced by MIF from autophagy-deficient cells.

Main Results:

  • Luminal B, HER2, and Basal breast cancer subtypes exhibit high MIF mRNA expression, but MIF lacks prognostic relevance.
  • Autophagy inhibition in 66cl4 TNBC cells elevates intracellular ROS, leading to increased MIF expression and secretion.
  • Secreted MIF activates pro-tumorigenic signaling pathways (Akt, ERK) in neighboring cancer cells.
  • TNBC cells show elevated CD74 and CXCR2, while the metastatic 4T1 cell line has increased CXCR7.
  • MIF from autophagy-deficient cells promotes M1 macrophage polarization.

Conclusions:

  • Autophagy inhibition in TNBC drives ROS-mediated MIF secretion, impacting cancer cell signaling.
  • Secreted MIF has paracrine effects on cancer cells and influences the tumor microenvironment via macrophage polarization.
  • Targeting autophagy inhibition requires careful consideration of its effects on MIF and associated signaling pathways in breast cancer therapy.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K